Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis
Open Access
- 10 January 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 9 (1), e1001154
- https://doi.org/10.1371/journal.pmed.1001154
Abstract
It is now a decade since the World Trade Organization (WTO) adopted the “Declaration on the TRIPS Agreement and Public Health” at its 4th Ministerial Conference in Doha. Many anticipated that these actions would lead nations to claim compulsory licenses (CLs) for pharmaceutical products with greater regularity. A CL is the use of a patented innovation that has been licensed by a state without the permission of the patent title holder. Skeptics doubted that many CLs would occur, given political pressure against CL activity and continued health system weakness in poor countries. The subsequent decade has seen little systematic assessment of the Doha Declaration's impact. We assembled a database of all episodes in which a CL was publically entertained or announced by a WTO member state since 1995. Broad searches of CL activity were conducted using media, academic, and legal databases, yielding 34 potential CL episodes in 26 countries. Country- and product-specific searches were used to verify government participation, resulting in a final database of 24 verified CLs in 17 nations. We coded CL episodes in terms of outcome, national income, and disease group over three distinct periods of CL activity. Most CL episodes occurred between 2003 and 2005, involved drugs for HIV/AIDS, and occurred in upper-middle-income countries (UMICs). Aside from HIV/AIDS, few CL episodes involved communicable disease, and none occurred in least-developed or low-income countries. Given skepticism about the Doha Declaration's likely impact, we note the relatively high occurrence of CLs, yet CL activity has diminished markedly since 2006. While UMICs have high CL activity and strong incentives to use CLs compared to other countries, we note considerable countervailing pressures against CL use even in UMICs. We conclude that there is a low probability of continued CL activity. We highlight the need for further systematic evaluation of global health governance actions. Please see later in the article for the Editors' SummaryThis publication has 11 references indexed in Scilit:
- A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countriesJournal of the International AIDS Society, 2010
- Trade, TRIPS, and pharmaceuticalsThe Lancet, 2009
- A proposal for measuring the degree of public health - sensitivity of patent legislation in the context of the WTO TRIPS AgreementBulletin of the World Health Organization, 2007
- TRIPS, the Doha Declaration and increasing access to medicines: policy options for GhanaGlobalization and Health, 2005
- Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?2004
- How Do Patents And Economic Policies Affect Access To Essential Medicines In Developing Countries?Health Affairs, 2004
- Managing the Provision of Knowledge: The Design of Intellectual Property LawsPublished by Oxford University Press (OUP) ,2003
- Public Health Triumphs at WTO ConferenceJAMA, 2001
- The WTO Dispute Settlement Understanding: An Unlikely Weapon in the Fight Against AIDSAmerican Journal of Law & Medicine, 2001
- The Global Drug GapScience, 2000